Halozyme and PTC Therapeutics: Near-Term Game-Changing PDUFAS
Some of the Prohost Portfolio selected companies are having near term PDUFAS which we believe will have a positive outcome. Indeed the FDA approvals are expected to tremendously boost these firms' values. Today we present two selected Biotech firms from the Prohost Portfolio.
Halozyme (HALO) has two upcoming importantThis content is for paid subscribers.
April 24, 2020